Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Roy Rampling"'
Autor:
James W.A. Ritchie, Sarah E. Halford, Harpreet Singh-Jasuja, Oliver Schoor, Karen Hill, Jane Peters, Lesley McGuigan, Norbert Hilf, Sarah Kutscher, Juha Lindner, Willie Stewart, Alan Jackson, Sarah Jefferies, Catherine McBain, Christopher J. Twelves, Omar Al-Salihi, Allan James, Paul J. Mulholland, Sharon Peoples, Roy Rampling
Supplementary Table S1. TUMAPs contained in IMA950 and associated source antigens. Supplementary Table S2. Statistical analysis underlying the recruitment of 20 immune evaluable patients per cohort. Supplementary Table S3. Reasons for HLA-A*02 positi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35bb952ed2561cc6de3f0f7698d8e249
https://doi.org/10.1158/1078-0432.22468137.v1
https://doi.org/10.1158/1078-0432.22468137.v1
Autor:
James W.A. Ritchie, Sarah E. Halford, Harpreet Singh-Jasuja, Oliver Schoor, Karen Hill, Jane Peters, Lesley McGuigan, Norbert Hilf, Sarah Kutscher, Juha Lindner, Willie Stewart, Alan Jackson, Sarah Jefferies, Catherine McBain, Christopher J. Twelves, Omar Al-Salihi, Allan James, Paul J. Mulholland, Sharon Peoples, Roy Rampling
Purpose: To perform a two-cohort, phase I safety and immunogenicity study of IMA950 in addition to standard chemoradiotherapy and adjuvant temozolomide in patients with newly diagnosed glioblastoma. IMA950 is a novel glioblastoma-specific therapeutic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24176b5389b980038b76490af7d1161f
https://doi.org/10.1158/1078-0432.c.6526851.v1
https://doi.org/10.1158/1078-0432.c.6526851.v1
Autor:
Chris J. Twelves, Alshad S. Lalani, Alvin Wong, Peter A. Harris, Chris R. Dunk, Egils Vjaters, Alan Anthoney, Chris Alcock, Neil Burnet, Roy Rampling, Roger M. Phillips, Philip H. Jones, Paul M. Loadman, Mark R. Albertella
Purpose: AQ4N is a novel bioreductive prodrug under clinical investigation. Preclinical evidence shows that AQ4N penetrates deeply within tumors and undergoes selective activation to form AQ4, a potent topoisomerase II inhibitor, in hypoxic regions o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::453fae2fae2fe778f3d3910b95e08d71
https://doi.org/10.1158/1078-0432.c.6516915.v1
https://doi.org/10.1158/1078-0432.c.6516915.v1
Autor:
Chris J. Twelves, Alshad S. Lalani, Alvin Wong, Peter A. Harris, Chris R. Dunk, Egils Vjaters, Alan Anthoney, Chris Alcock, Neil Burnet, Roy Rampling, Roger M. Phillips, Philip H. Jones, Paul M. Loadman, Mark R. Albertella
Supplementary Tables S1-S5 from Hypoxia-Selective Targeting by the Bioreductive Prodrug AQ4N in Patients with Solid Tumors: Results of a Phase I Study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3de084c3a0b5fd417852841501f36f6a
https://doi.org/10.1158/1078-0432.22439448
https://doi.org/10.1158/1078-0432.22439448
Autor:
Paul Mulholland, Oliver Schoor, Omar Al-Salihi, Chris Twelves, Juha Lindner, Harpreet Singh-Jasuja, Sharon Peoples, Alan Jackson, Sarah Halford, James W A Ritchie, Lesley McGuigan, Catherine McBain, Roy Rampling, Sarah Kutscher, Allan James, Willie Stewart, Norbert Hilf, Jane Peters, Sarah Jefferies, Karen Hill
Publikováno v:
Clinical Cancer Research. 22:4776-4785
Purpose: To perform a two-cohort, phase I safety and immunogenicity study of IMA950 in addition to standard chemoradiotherapy and adjuvant temozolomide in patients with newly diagnosed glioblastoma. IMA950 is a novel glioblastoma-specific therapeutic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33e4ea4b12f63a0322a23115c9d48b3b
https://doi.org/10.1158/1078-0432.ccr-16-0506
https://doi.org/10.1158/1078-0432.ccr-16-0506
Autor:
S. McNamara, Robin Grant, Alan Carson, Mairi Mackinnon, Mary Fraser, Alasdair G Rooney, Roy Rampling
Publikováno v:
Neuro-Oncology. 15:122-129
No depression screening tool is validated for use in cases of cerebral glioma. To address this, we studied the operating characteristics of the Hospital Anxiety and Depression Scale (Depression subscale) (HAD-D), the Patient Health Questionnaire-9 (P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18e461037893425c5eabfa0fc869da80
https://doi.org/10.1093/neuonc/nos282
https://doi.org/10.1093/neuonc/nos282
Autor:
Sarah Jefferies, B Haylock, Jeremy Rees, C Soh, Roy Rampling, I R Whittle, Catherine McBain, Paul Sanghera
Publikováno v:
Clinical Oncology. 24:216-227
Since postoperative radiotherapy plus concomitant temozolomide followed by adjuvant temozolomide has become standard treatment for glioblastoma, the phenomenon of early post-treatment enlargement of the imaged tumour volume, usually without clinical
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e7cdefcb1789ecf73daf2c38b804dfc3
https://doi.org/10.1016/j.clon.2011.06.004
https://doi.org/10.1016/j.clon.2011.06.004
Autor:
Thierry Gorlia, Eric Raymond, Alba A. Brandes, Pierre Fumoleau, Monika E. Hegi, Roger Stupp, Denis Lacombe, Christian Dittrich, Roy Rampling, Martin J. van den Bent, Chris Twelves, Mario Campone
Publikováno v:
European Journal of Cancer, 48(8), 1176-1184. Elsevier Ltd.
Background: Prognostic models have been developed to predict survival of patients with newly diagnosed glioblastoma (GBM). To improve predictions, models should be updated with information at the recurrence. We performed a pooled analysis of European
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::977ee486600ebe96a15f893c48c7a3fd
https://pure.eur.nl/en/publications/421b7219-2f04-4ac9-8ff0-feba77dc63d2
https://pure.eur.nl/en/publications/421b7219-2f04-4ac9-8ff0-feba77dc63d2
Autor:
Thiery Gorlia, Marc Sanson, Clemens Stoffregen, Martin J. van den Bent, Myriam Gharib, Christina Lai, Denis Lacombe, Walter Taal, Roy Rampling, Rodney Decker
Publikováno v:
Neuro-Oncology, 14(3), 344-350. Oxford University Press
We report a phase 1 study to examine the safety and recommended dose of the oral protein kinase C-beta inhibitor (anti-angiogenic) enzastaurin in combination with single-agent temozolomide. The study was conducted in patients with recurrent glioblast
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a888199d5eaf9887e421b7039cdfdbe
https://pure.eur.nl/en/publications/9bc3824b-3247-4fa4-9840-14ad8ddd7010
https://pure.eur.nl/en/publications/9bc3824b-3247-4fa4-9840-14ad8ddd7010
Autor:
Pierre Fumoleau, Mario Campone, Chris Twelves, Denis Lacombe, M. J. van den Bent, Roy Rampling, Bruno Coudert, C. de Balincourt, M.J.A. de Jonge, C. Dittrich, Roberto Sorio
Publikováno v:
Annals of Oncology, 13, 777-780. Elsevier Ltd.
Background XR5000 is a tricyclic carboxamide that intercalates DNA and inhibits both topoisomerase I and II. The aim of this study was to evaluate the efficacy and tolerability of XR5000 in patients with recurrent glioblastoma multiforme previously u
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c2e766ef5a5e29611168d0f898a3973
https://doi.org/10.1093/annonc/mdf121
https://doi.org/10.1093/annonc/mdf121